Projects per year
Fingerprint
Dive into the research topics where M Maral Mouradian is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
PME-1: Pathogenetic Role and Therapeutic Opportunity in Neurodegenerative Mixed Proteinopathies
Mouradian, M. M. (PI)
National Institute of Neurological Disorders and Stroke
3/1/26 → 2/28/27
Project: Research project
-
PME-1: Pathogenetic Role and Therapeutic Opportunity in Neurodegenerative Mixed Proteinopathies
Mouradian, M. M. (PI)
National Institute of Neurological Disorders and Stroke
3/1/23 → 2/28/26
Project: Research project
-
Role of Transglutaminase 2 in Synucleinopathies
Mouradian, M. M. (PI)
National Institute of Neurological Disorders and Stroke
7/1/21 → 12/31/22
Project: Research project
-
Training in Translating Neuroscience to Therapies
Mouradian, M. M. (CoPI) & Mouradian, M. M. M. (PI)
National Institute of Neurological Disorders and Stroke
7/1/21 → 6/30/26
Project: Research project
-
RNA Targeted Drug Discovery and Development for Parkinson Disease
Mouradian, M. M. (PI) & Disney, M. D. (CoPI)
National Institute of Neurological Disorders and Stroke
6/1/21 → 5/31/23
Project: Research project
-
Protein phosphatase 2A methylation state impacts α-synucleinopathy in mouse models
Maddila, S., Hassanzadeh, K., Liu, J., Zhang, J., Ullah, F., Nichols, R. E. & Mouradian, M. M., Dec 2026, In: Cell Death Discovery. 12, 1, 172.Research output: Contribution to journal › Article › peer-review
Open Access1 Link opens in a new tab Scopus citations -
The cross-linking activity of transglutaminase 2 drives α-Synuclein pathology in synucleinopathy models
Hassanzadeh, K., Liu, J., Zhang, J., Tabari, M. A., Maddila, S. & Mouradian, M. M., Mar 24 2026, In: Proceedings of the National Academy of Sciences of the United States of America. 123, 12, e2517886123.Research output: Contribution to journal › Article › peer-review
Open Access -
Advances in Disease Modifying Therapies for Parkinson’s Disease
Hassanzadeh, K. & Mouradian, M. M., Jan 1 2025, Trends in CNS Drug Discovery. wiley, p. 17-66 50 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter
1 Link opens in a new tab Scopus citations -
Disease-Modifying Trials in Treated Parkinson's Disease: “Stable Treated” Does Not Equate with Biological Stability
Mouradian, M. M., Stoessl, A. J. & Lang, A. E., Sep 2025, In: Movement Disorders. 40, 9, p. 1778-1790 13 p.Research output: Contribution to journal › Review article › peer-review
Open Access4 Link opens in a new tab Scopus citations -
Increased burden of rare risk variants across gene expression networks predisposes to sporadic Parkinson's disease
Eubanks, E., VanderSleen, K., Mody, J., Patel, N., Sacks, B., Farahani, M. D., Wang, J., Elliott, J., Jaber, N., Akçimen, F., Bandres-Ciga, S., Helweh, F., Liu, J., Archakam, S., Kimelman, R., Sharma, B., Socha, P., Guntur, A., Huang, Y. & Ramalingam, N. & 10 others, , May 27 2025, In: Cell Reports. 44, 5, 115636.Research output: Contribution to journal › Article › peer-review
Open Access4 Link opens in a new tab Scopus citations